Quest Research Institute — Biomedical Watch V2

Essais liés21clinical trials

VilleFarmington Hillslocalisation

PaysUnited Stateslocalisation

SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT06544616

Ouvrir le site du centre

Essais cliniques associés

Molécule	Indication / population	Phase	NCT	Titre	Statut
RO7126209	Alzheimer	Phase 1/2	NCT04639050	Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease	ACTIVE_NOT_RECRUITING
Prasinezumab	Parkinson	Phase 2	NCT04777331	PADOVA — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease	ACTIVE_NOT_RECRUITING
RO7046015	Parkinson	Phase 2	NCT03100149	PASADENA — A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease	ACTIVE_NOT_RECRUITING
Zunveyl®	Alzheimer	Phase 4	NCT07633470	A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)	RECRUITING
NEU-411	Parkinson	Phase 2	NCT06680830	NEULARK — A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease	RECRUITING
LY4405094	Alzheimer	Phase 1	NCT07787169	A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease	NOT_YET_RECRUITING
Donanemab	Alzheimer	Phase 3	NCT04437511	A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)	ACTIVE_NOT_RECRUITING
LY4405094	Alzheimer	Phase 1	NCT07787182	A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease	NOT_YET_RECRUITING
JNJ-64042056	Alzheimer	Phase 2	NCT06544616	Reτain — A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease	ACTIVE_NOT_RECRUITING
Donanemab	Alzheimer	Phase 2	NCT07589595	A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)	RECRUITING
Trontinemab	Alzheimer	Phase 3	NCT07170150	TRONTIER 2 — A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease	RECRUITING
bemdaneprocel	Parkinson	Phase 3	NCT06944522	exPDite-2 — A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease	RECRUITING
Prasinezumab	Parkinson	Phase 3	NCT07174310	PARAISO — A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease	RECRUITING
MTX101	Migraine	Phase 2	NCT06728553	Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults	COMPLETED
KarXT	Alzheimer	Phase 3	NCT06976203	A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)	RECRUITING
HBI-002	Parkinson	Phase 2	NCT07005180	LoCaMoTE-PD — Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease	RECRUITING
NE3107	Parkinson	Phase 2	NCT06757010	SUNRISE-PD — A Study of NE3107 in Early Parkinson's	COMPLETED
APL-130277	Parkinson	Phase 3	NCT02542696	Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease	COMPLETED
Botulinum toxin type A	Migraine	Phase 3	NCT06047457	E-BEOND — A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults	ACTIVE_NOT_RECRUITING
Botulinum toxin type A	Migraine	Phase 3	NCT06047444	C-BEOND — A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults	ACTIVE_NOT_RECRUITING
CVN424 75 mg	Parkinson	Phase 3	NCT06553027	To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications	ACTIVE_NOT_RECRUITING